Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
royalty payments
Biotech
Teva's $400M Blackstone deal to fund Sanofi-partnered IBD drug
The cash will be spread across four years to fund development of the anti-TL1A antibody duvakitug.
James Waldron
Mar 4, 2026 3:07am
Candel glows with $100M RTW deal to fund cancer drug launch
Feb 20, 2026 4:04am
Royalty bestows Zenas with $300M for autoimmune approval push
Sep 2, 2025 11:07am
RegenXBio sells $250M of paydays for Zolgensma, other therapies
May 20, 2025 7:15am
Investors say 'no bueno' to Cytokinetics' complex Royalty deal
May 23, 2024 10:36am
BridgeBio taps investors for $1.25B to fund showdown with Pfizer
Jan 18, 2024 8:04am
